THE WIRE · № 72793
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
01 THE MACHINE READ
WHY IT MATTERS.
Exploratory Phase 3b biomarker data linking immune and metabolic biology supports Lilly's combined Taltz and Zepbound franchise narrative.
Lilly deepens obesity-immunology crossover evidence base
Further trial readouts or regulatory filings
Exploratory data may not translate to approval
FULL DISPATCH
Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis2026-10-09 11:00 UTC
Fidelity-Backed City Therapeutics Seeks $184.7 Million in US IPO2026-10-09 11:15 UTC
TRex Bio prices $117M IPO to support immune drug work2026-10-09 11:22 UTC
Leading Through a Changing Water Management Landscape2026-10-09 11:40 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.